# SixPeaks Bio AG Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sixpeaks-bio-ag-therapeutics

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Total disclosed funding: $30M
- Latest round: Series A (May 22, 2024)
- Investors on record: 2

## About

Based in Basel, Switzerland, and founded in 2022, SixPeaks Bio AG Therapeutics operates as a biopharmaceutical company developing therapeutic dietary drugs. In May 2024, the firm raised USD 30 million in series A funding led by investors Versant Ventures, with participation from another investor AstraZenec.

The company develops therapies and medicines for healthy weight loss and metabolic fitness. SixPeaks Bio targets muscle preservation while promoting weight loss, addressing a critical gap in obesity treatments. The pipeline of therapies offered by the company includes a dual-specific antibody targeting activin type IIA and B receptors. This antibody aims to preserve skeletal muscle mass while facilitating weight loss, enhancing the efficacy and long-term utility of GLP-1-based therapies, which traditionally result in significant muscle loss.

The company plans to utilize the May 2024 funding to widen its market presence and accelerate its research and development initiatives.

## Funding rounds

- Series A, May 22, 2024, $30M — Versant Ventures, AstraZeneca

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- AstraZeneca — Series A